Revolutionizing Biopharmaceuticals: Longevity Biomedical Inc. and FutureTech II Acquisition Corp. Join Forces to Create Nasdaq-Listed Company Focused on Advancing Cutting-Edge Technologies
Longevity Biomedical and FutureTech Announce Business Combination Agreement New York, Sept. 20, 2024 (GLOBE NEWSWIRE) — Longevity Biomedical, Inc. (“Longevity” or “Longevity Biomedical”), a biopharmaceutical company focused on advancing new technologies across therapeutics, health monitoring, and digital health solutions to increase human health span, and FutureTech II Acquisition Corp. (“FutureTech”) (NASDAQ: FTII), a publicly traded…